Wegovy 1.7mg
Semaglutide injection 1.7 mg · prescription medicine · licensed healthcare professionals only.
$490.90
- Wegovy 2.4 mg is the highest dosage in this FDA-approved weight management program and is intended as the maintenance phase of treatment. This dose is clinically proven to help individuals sustain long-term weight loss by stabilizing appetite and reinforcing healthy lifestyle changes. As part of a comprehensive program involving dietary adjustments and regular physical activity, Wegovy 2.4 mg supports ongoing progress and prevents weight regain. With its proven safety and efficacy, this maintenance dose helps you achieve sustainable results, empowering you to lead a healthier, more fulfilling life.
Professional use only. This product is intended for administration by licensed healthcare practitioners trained in the relevant anatomy and injection technique. By ordering you confirm you are authorised to purchase and handle products of this class in your jurisdiction. Availability and permitted use vary by country — please verify local regulations before ordering.
Did you like this product? Add to favorites now and follow the product.
(+82) 10 7364 7998 Send a message on WhatsApp.
Wegovy 1.7 mg: semaglutide injection for chronic weight management
Wegovy (semaglutide) is a prescription GLP-1 receptor agonist from Novo Nordisk. It is used, together with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain the reduction in adults and children aged 12 and over with obesity, and in adults with overweight who also have a weight-related condition. In the US it is also indicated to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.
1.7 mg is one of the strengths in the labelled stepwise escalation plan, between 1 mg and 2.4 mg. Wegovy is a prescription-only medicine. We supply it to licensed healthcare professionals and licensed pharmacies only, and the prescriber decides which strength a patient receives and for how long.
A GLP-1 receptor agonist taken as a once-weekly injection.
1 pre-filled pen providing 4 weekly doses, with 4 disposable needles.
Strength and duration are set by the prescriber for each patient.
Supplied to licensed healthcare professionals and pharmacies only.
About Wegovy 1.7 mg
Wegovy is the semaglutide brand from Novo Nordisk approved for chronic weight management.
1.7 mg is one of the steps in the labelled escalation plan.
The label indicates use with a reduced-calorie diet and increased physical activity.
Given once a week by subcutaneous injection into the abdomen, thigh or upper arm.
Labelled indications
As listed in the current US prescribing information for Wegovy injection. Indications differ between countries; check the local label.
Adults and children aged 12 and over with obesity, together with a reduced-calorie diet and increased physical activity.
Adults with overweight who have at least one weight-related condition.
Adults with established cardiovascular disease and either obesity or overweight.
Adults with non-cirrhotic MASH with moderate to advanced fibrosis. This US indication was granted under accelerated approval.
Wegovy is a prescription medicine. Which indications are approved, who may prescribe and dispense it, and whether it can be imported are set by the regulatory framework where you practise. Nothing here is medical advice.
Wegovy 1.7 mg at a glance
| Active substance | Semaglutide |
| Strength | 1.7 mg per weekly dose |
| Form | Solution for subcutaneous injection in a pre-filled pen |
| Pack | 1 pre-filled pen providing 4 weekly doses, with 4 disposable needles and an instruction manual |
| Brand owner | Novo Nordisk |
| Storage | Refrigerate at 2 °C to 8 °C. Do not freeze. |
Before you order
- Prescription medicine. Wegovy is a prescription-only product. We supply licensed healthcare professionals and licensed pharmacies only. Rules on prescribing, importing and supplying it differ between countries, and the buyer is responsible for making sure the purchase and use are lawful where they practise.
- Boxed warning (US label): semaglutide caused thyroid C-cell tumours in rodents, and whether it does so in humans is unknown. It must not be used in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.
- Every pack ships with its lot number and expiry date. We do not dispatch stock with under 6 months of shelf life remaining unless agreed in advance.
- The cold chain matters for this product. See Storage.
What each component does
Semaglutide
Semaglutide is a GLP-1 receptor agonist. GLP-1 is a gut hormone involved in appetite and in how the stomach empties. The medicine is used together with diet and physical activity.
The full list of excipients is in the patient leaflet supplied with the pen.
How Wegovy is used
General information for healthcare professionals. The prescriber and the product leaflet decide the strength, schedule and duration for each patient. This page does not give a dosing plan.
Step by step
-
Prescriber assessment
A prescriber confirms the indication and checks the contraindications and warnings listed below, including thyroid history, pancreatitis, gallbladder disease and diabetes treatment.
-
Strength chosen by the prescriber
Wegovy is escalated in steps under the prescriber’s direction. 1.7 mg is one of the strengths in the labelled plan.
-
Weekly injection
Given under the skin of the abdomen, thigh or upper arm, once a week, following the leaflet.
-
Used with lifestyle measures
The label indicates use alongside a reduced-calorie diet and increased physical activity.
-
Follow-up
The prescriber reviews tolerability and response, and decides whether to move to another strength.
Administration notes
Do not combine with other GLP-1 products. The US label does not recommend use with other semaglutide-containing products or any other GLP-1 receptor agonist.
- Patients on insulin or sulfonylureas may need their dose reviewed because of hypoglycaemia risk.
- Wegovy delays gastric emptying and may affect the absorption of oral medicines.
- Patients should tell their care team about planned surgery or procedures that need anaesthesia or deep sedation.
- Dispose of sharps in a sharps container.
Storing and handling Wegovy 1.7 mg
Store at 2 °C to 8 °C. Do not freeze, and do not use a pen that has been frozen.
If needed, pens can be kept below 30 °C for up to 28 days.
Keep the pen in its original pack or with the cap on, away from direct light and heat.
Do not use a pen that has been frozen, is damaged, or contains discoloured liquid or particles. Dispose of used pens and needles in a sharps container in line with local rules.
What's in the pack
Supplied in the original manufacturer’s pack.
Wegovy 1.7 mg — frequently asked questions
What is Wegovy?
A prescription semaglutide injection from Novo Nordisk, used with a reduced-calorie diet and increased physical activity for chronic weight management.
What is the 1.7 mg strength?
It is one of the strengths in the labelled escalation plan. The prescriber decides which strength each patient uses and for how long.
Who can buy it?
Licensed healthcare professionals and licensed pharmacies only. It is a prescription medicine and we do not sell to consumers.
How long does one pen last?
Each pen provides four weekly doses, so it lasts four weeks.
Who must not use it?
People with a personal or family history of medullary thyroid carcinoma, with Multiple Endocrine Neoplasia syndrome type 2, or with a known allergy to semaglutide or any excipient. It is not for use in pregnancy.
What are the common side effects?
The US label lists nausea, diarrhoea, vomiting, constipation and abdominal pain among the most common. More serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration and allergic reactions. Patients with severe or persistent symptoms should contact their healthcare provider.
How should it be stored?
In the refrigerator at 2 °C to 8 °C. Do not freeze.
Copyright 2026 © Korea Filler Experts. All right reserved.
